FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104913743> ?p ?o ?g. }

• W2104913743 endingPage "1140" @default.
• W2104913743 startingPage "1130" @default.
• W2104913743 abstract "Objective The safety and tolerability of three treatments for diabetic peripheral neuropathic pain (DPNP) were compared. Methods A 12-week, randomized, open-label study confirming the non-inferiority of duloxetine (N = 138) vs. pregabalin (N = 134) and the combination of duloxetine plus gabapentin (N = 135) as the primary outcome was previously published. Patients had an inadequate pain response to a stable dose of gabapentin (≥ 900 mg/day) for ≥ 5 weeks prior to study enrolment. Data from that study were assessed in this current analysis for a detailed report of safety and tolerability. Results Completion rates did not differ significantly between the groups. Discontinuation because of adverse events was significantly greater in the duloxetine (19.6%) vs. pregabalin group (10.4%; p = 0.04); no differences emerged between the duloxetine vs. duloxetine plus gabapentin (13.3%) groups (p = 0.19) or pregabalin vs. duloxetine plus gabapentin groups (p = 0.57). Adverse event rates varied: nausea, insomnia, hyperhidrosis and decreased appetite were reported significantly more often in patients treated with duloxetine vs. patients treated with pregabalin (each p ≤ 0.01); insomnia significantly more in patients treated with duloxetine vs. duloxetine plus gabapentin (p = 0.01); peripheral oedema significantly more in patients treated with pregabalin vs. duloxetine and duloxetine plus gabapentin (p ≤ 0.001 each) and nausea, hyperhidrosis, decreased appetite and vomiting significantly more in patients treated with duloxetine plus gabapentin vs. pregabalin (each p ≤ 0.05). At end-point, weight change differed significantly among treatment groups: patients in the pregabalin group on average gained weight (1.0 ± 0.04 kg); while, patients in the duloxetine and duloxetine plus gabapentin groups on average lost weight (−2.39 ± 0.04 and −1.06 ± 0.04 kg, respectively) (pregabalin vs. duloxetine, p ≤ 0.001; pregabalin vs. duloxetine plus gabapentin, p ≤ 0.001; duloxetine vs. duloxetine plus gabapentin, p = 0.01). Conclusion Duloxetine, pregabalin and duloxetine plus gabapentin were generally safe and tolerable for the treatment of DPNP." @default.
• W2104913743 created "2016-06-24" @default.
• W2104913743 creator A5051916988 @default.
• W2104913743 creator A5062707923 @default.
• W2104913743 creator A5063618224 @default.
• W2104913743 creator A5064245192 @default.
• W2104913743 creator A5087807022 @default.
• W2104913743 date "2014-05-18" @default.
• W2104913743 modified "2023-09-26" @default.
• W2104913743 title "Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain" @default.
• W2104913743 cites W1573357728 @default.
• W2104913743 cites W1845521331 @default.
• W2104913743 cites W1965829294 @default.
• W2104913743 cites W1974576315 @default.
• W2104913743 cites W1983795212 @default.
• W2104913743 cites W1984259090 @default.
• W2104913743 cites W1986578760 @default.
• W2104913743 cites W1997057293 @default.
• W2104913743 cites W2001322197 @default.
• W2104913743 cites W2008571936 @default.
• W2104913743 cites W2008600729 @default.
• W2104913743 cites W2014670473 @default.
• W2104913743 cites W2018425549 @default.
• W2104913743 cites W2020407769 @default.
• W2104913743 cites W2029572600 @default.
• W2104913743 cites W2031723890 @default.
• W2104913743 cites W2042071004 @default.
• W2104913743 cites W2043595892 @default.
• W2104913743 cites W2072534151 @default.
• W2104913743 cites W2072772870 @default.
• W2104913743 cites W2076619852 @default.
• W2104913743 cites W2081325201 @default.
• W2104913743 cites W2084258035 @default.
• W2104913743 cites W2090925937 @default.
• W2104913743 cites W2103289578 @default.
• W2104913743 cites W2106059433 @default.
• W2104913743 cites W2114586172 @default.
• W2104913743 cites W2120306614 @default.
• W2104913743 cites W2121784904 @default.
• W2104913743 cites W2125761169 @default.
• W2104913743 cites W2143017058 @default.
• W2104913743 cites W2148097499 @default.
• W2104913743 cites W2149813500 @default.
• W2104913743 cites W2329242769 @default.
• W2104913743 doi "https://doi.org/10.1111/ijcp.12452" @default.
• W2104913743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24837444" @default.
• W2104913743 hasPublicationYear "2014" @default.
• W2104913743 type Work @default.
• W2104913743 sameAs 2104913743 @default.
• W2104913743 citedByCount "22" @default.
• W2104913743 countsByYear W21049137432016 @default.
• W2104913743 countsByYear W21049137432017 @default.
• W2104913743 countsByYear W21049137432018 @default.
• W2104913743 countsByYear W21049137432019 @default.
• W2104913743 countsByYear W21049137432020 @default.
• W2104913743 countsByYear W21049137432021 @default.
• W2104913743 countsByYear W21049137432022 @default.
• W2104913743 countsByYear W21049137432023 @default.
• W2104913743 crossrefType "journal-article" @default.
• W2104913743 hasAuthorship W2104913743A5051916988 @default.
• W2104913743 hasAuthorship W2104913743A5062707923 @default.
• W2104913743 hasAuthorship W2104913743A5063618224 @default.
• W2104913743 hasAuthorship W2104913743A5064245192 @default.
• W2104913743 hasAuthorship W2104913743A5087807022 @default.
• W2104913743 hasBestOaLocation W21049137431 @default.
• W2104913743 hasConcept C126322002 @default.
• W2104913743 hasConcept C142724271 @default.
• W2104913743 hasConcept C197934379 @default.
• W2104913743 hasConcept C204787440 @default.
• W2104913743 hasConcept C2776468701 @default.
• W2104913743 hasConcept C2776608144 @default.
• W2104913743 hasConcept C2777107010 @default.
• W2104913743 hasConcept C2778375690 @default.
• W2104913743 hasConcept C2780580376 @default.
• W2104913743 hasConcept C2780764818 @default.
• W2104913743 hasConcept C2910564767 @default.
• W2104913743 hasConcept C42219234 @default.
• W2104913743 hasConcept C71924100 @default.
• W2104913743 hasConceptScore W2104913743C126322002 @default.
• W2104913743 hasConceptScore W2104913743C142724271 @default.
• W2104913743 hasConceptScore W2104913743C197934379 @default.
• W2104913743 hasConceptScore W2104913743C204787440 @default.
• W2104913743 hasConceptScore W2104913743C2776468701 @default.
• W2104913743 hasConceptScore W2104913743C2776608144 @default.
• W2104913743 hasConceptScore W2104913743C2777107010 @default.
• W2104913743 hasConceptScore W2104913743C2778375690 @default.
• W2104913743 hasConceptScore W2104913743C2780580376 @default.
• W2104913743 hasConceptScore W2104913743C2780764818 @default.
• W2104913743 hasConceptScore W2104913743C2910564767 @default.
• W2104913743 hasConceptScore W2104913743C42219234 @default.
• W2104913743 hasConceptScore W2104913743C71924100 @default.
• W2104913743 hasIssue "9" @default.
• W2104913743 hasLocation W21049137431 @default.
• W2104913743 hasLocation W21049137432 @default.
• W2104913743 hasOpenAccess W2104913743 @default.
• W2104913743 hasPrimaryLocation W21049137431 @default.
• W2104913743 hasRelatedWork W2014185462 @default.
• W2104913743 hasRelatedWork W2080027527 @default.

• next